4.23% -0.045

Scynexis Inc (SCYX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SCYX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1154)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SCYX's Discussions on Twitter

Vergleichen Sie SCYX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SCYX Scynexis Inc	1.02	35.86M	135.87M	72.20M	45.09M	1.42
ZTS Zoetis Inc	153.47	65.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	46.99B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.18	45.96B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	14.87	17.04B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	291.38	12.77B	2.76B	1.11B	898.10M	22.77

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-01-22	Eingeleitet	Guggenheim	Buy
2021-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2018-07-11	Hochstufung	Needham	Hold → Buy
2018-06-27	Eingeleitet	Maxim Group	Buy
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-10	Eingeleitet	ROTH Capital	Buy
2017-05-09	Herabstufung	Needham	Buy → Hold
2017-03-03	Bestätigt	RBC Capital Mkts	Outperform
2016-10-20	Eingeleitet	H.C. Wainwright	Buy
2016-10-07	Hochstufung	WBB Securities	Buy → Strong Buy
2016-10-03	Fortgesetzt	Brean Capital	Buy
2016-08-17	Eingeleitet	Guggenheim	Buy
2016-08-09	Bestätigt	Needham	Buy
2016-08-09	Hochstufung	WBB Securities	Speculative Buy → Buy
2016-03-28	Eingeleitet	Brean Capital	Buy
2015-12-29	Eingeleitet	WBB Securities	Speculative Buy
2015-11-16	Bestätigt	RBC Capital Mkts	Outperform
2015-06-10	Eingeleitet	Needham	Buy
2014-05-29	Eingeleitet	Canaccord Genuity	Buy
2014-05-29	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

Vergleichen Sie SCYX mit anderen Aktien

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

Press Release Distribution & PR Platform - ACCESS Newswire

SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World

Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com

Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com

SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa

SCY-247 shows promise against resistant fungal infections - Investing.com

Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Scynexis Inc earnings beat by $0.06, revenue fell short of estimates - Investing.com Australia

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart - Nasdaq

SCYX stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound - BioSpace

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017SCYX - ACCESS Newswire

SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire

SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World

Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com

Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail

SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World

Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.

SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com

SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times

SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan

SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada

Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World

SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St

Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com

Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com

SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa

SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com

SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SCYX